💊 Fármacos A-Z 🧬 Dianas 🛠 Herramientas 📚 Guías
Todos los fármacos Clases de fármacos Áreas terapéuticas Efectos Secundarios
Guías Glosario Línea de tiempo
Comparaciones Recorridos de fármacos Familias farmacológicas
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Sitagliptin Fumarate

CHEMBL5315049 Phase 4 Aprobado Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
523.4 g/mol
LogP
—
Phase
4

A fumarate salt form of sitagliptin with the same therapeutic properties. This once-daily pill helps control blood sugar in type 2 diabetes by preventing the breakdown of incretin hormones that naturally stimulate insulin release after eating.

Peso molecular

523,4000 g/mol

TPSA

152,00 Ų

Mecanismo de acción

DPP-4 inhibitor increasing incretin levels.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

DPP-4 inhibitor increasing incretin levels.

Estructura 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F.O=C(O)/C=C\C(=O)O

                

                

                
                

                    
InChI

                    
InChI=1S/C16H15F6N5O.C4H4O4/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22;5-3(6)1-2-4(7)8/h4,6,9H,1-3,5,7,23H2;1-2H,(H,5,6)(H,7,8)/b;2-1-/t9-;/m1./s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C20H19F6N5O5

                    

                    
                    

                        
HBD / HBA

                        
3 / 14

                    

                    
                    

                        
Enlaces Rotables

                        
6

                    

                    
                    
                    

                        
Átomos Pesados

                        
36

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Preguntas frecuentes

                

                    
                    

                        
                        

                            
A fumarate salt form of sitagliptin with the same therapeutic properties. This once-daily pill helps control blood sugar in type 2 diabetes by preventing the breakdown of incretin hormones that naturally stimulate insulin release after eating.

                        

                    

                    

                    

                    
                    

                        
                        

                            
DPP-4 inhibitor increasing incretin levels.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Sitagliptin Fumarate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL5315049.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 11386885.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Aviso médico

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.